Increased Activation Markers of Adaptive Immunity in Patients with Severe COVID-19

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Oct 16

PMID 39407725

Authors

Abdulelah Aljuaid

Affiliations

Soon will be listed here.

Abstract

COVID-19 is a pandemic disease and is widespread over the world. This disease shows a 5.1% mortality. The understanding of the disease has expanded rapidly in many areas, including virological, epidemiological, clinical, and management dimensions. To better understand the inflammatory and immune profiles that impact the pathogenesis and development of severe COVID-19 symptoms, further studies are essential. This research aims to explore the inflammatory and adaptive immune responses associated with COVID-19, considering factors such as genetic diversity and environmental exposure among Saudi patients. The goal is to determine if patients with severe COVID-19 exhibit different disease phenotypes. This case-control study includes 115 participants (healthy and with COVID-19 infection), 55 of which had confirmed cases of COVID-19 in intensive care units (ICUs) at different hospitals in Makkah City, Saudi Arabia. Whole blood samples were collected from June to September 2021 for cellular analyses, and inflammation marker data were collected from hospital records. The expression of activation markers on B (CD27 and CD38) and T cells (CD27 and HLA-DR) was obtained using the flow cytometry technique. Also, serum was collected for cytokine measurements, including IL-6, INF-γ, and TNF- α. The results indicated that lymphopenia and excessive T cell activation were more prevalent in severe cases than in healthy individuals. Furthermore, the results revealed that severe COVID-19 patients had an increased frequency of CD19+ B cells, with changes in B cell subsets. The current study implies impairment and changes in the phenotype of adaptive cells (including T and B cells), with an increase in HLA-DR molecules and inflammation markers with pro-inflammatory cytokines in severe COVID-19 cases. The current study implies impairment and changes in the phenotype of adaptive cells (including T and B cells), with an increase in HLA-DR molecules and inflammation markers in severe COVID-19 cases, which could be targeted for therapeutic interventions. This might be a valuable approach for the diagnosis and treatment of severe COVID-19 cases.

References

Guarner J . Three Emerging Coronaviruses in Two Decades. Am J Clin Pathol. 2020; 153(4):420-421. PMC: 7109697. DOI: 10.1093/ajcp/aqaa029. View

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

Rabaan A, Al-Ahmed S, Muhammad J, Khan A, Sule A, Tirupathi R . Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm. Vaccines (Basel). 2021; 9(5). PMC: 8145892. DOI: 10.3390/vaccines9050436. View

Allahyani M, Aljuaid A, Almehmadi M, Alghamdi A, Halawani I, Aldairi A . Detection of erythroid progenitors and erythrocytopathies in patients with severe COVID-19 disease. Saudi Med J. 2022; 43(8):899-906. PMC: 9749667. DOI: 10.15537/smj.2022.43.8.20220311. View

Xiao B, Wu Y, Liang H, Xiao J, Han Y, Yang Z . C-reactive protein to lymphocyte ratio is a significant predictive factor for poor short-term clinical outcomes of SARS-CoV-2 BA.2.2 patients. Front Public Health. 2023; 11:1168375. PMC: 10117655. DOI: 10.3389/fpubh.2023.1168375. View

Wolfel R, Corman V, Guggemos W, Seilmaier M, Zange S, Muller M . Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581(7809):465-469. DOI: 10.1038/s41586-020-2196-x. View

Driggin E, Madhavan M, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G . Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol. 2020; 75(18):2352-2371. PMC: 7198856. DOI: 10.1016/j.jacc.2020.03.031. View

Pfortmueller C, Meisel C, Fux M, Schefold J . Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers. Intensive Care Med Exp. 2017; 5(1):49. PMC: 5653680. DOI: 10.1186/s40635-017-0163-0. View

Song J, Zhang C, Fan X, Meng F, Xu Z, Xia P . Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun. 2020; 11(1):3410. PMC: 7343781. DOI: 10.1038/s41467-020-17240-2. View

10.

Teuwen L, Geldhof V, Pasut A, Carmeliet P . COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020; 20(7):389-391. PMC: 7240244. DOI: 10.1038/s41577-020-0343-0. View

11.

Du J, Wei L, Li G, Hua M, Sun Y, Wang D . Persistent High Percentage of HLA-DRCD38 CD8 T Cells Associated With Immune Disorder and Disease Severity of COVID-19. Front Immunol. 2021; 12:735125. PMC: 8458852. DOI: 10.3389/fimmu.2021.735125. View

12.

Gupta A, Madhavan M, Sehgal K, Nair N, Mahajan S, Sehrawat T . Extrapulmonary manifestations of COVID-19. Nat Med. 2020; 26(7):1017-1032. DOI: 10.1038/s41591-020-0968-3. View

13.

Lechien J, Chiesa-Estomba C, Place S, Van Laethem Y, Cabaraux P, Mat Q . Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020; 288(3):335-344. PMC: 7267446. DOI: 10.1111/joim.13089. View

14.

Mehta P, McAuley D, Brown M, Sanchez E, Tattersall R, Manson J . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229):1033-1034. PMC: 7270045. DOI: 10.1016/S0140-6736(20)30628-0. View

15.

Cai B, Cui Y, Zhou J, Wang Y, Yang L, Tan B . Asymmetric Hydrophosphinylation of Alkynes: Facile Access to Axially Chiral Styrene-Phosphines. Angew Chem Int Ed Engl. 2022; 62(3):e202215820. DOI: 10.1002/anie.202215820. View

16.

Sosa-Hernandez V, Torres-Ruiz J, Cervantes-Diaz R, Romero-Ramirez S, Paez-Franco J, Meza-Sanchez D . B Cell Subsets as Severity-Associated Signatures in COVID-19 Patients. Front Immunol. 2020; 11:611004. PMC: 7744304. DOI: 10.3389/fimmu.2020.611004. View

17.

Tippalagama R, Singhania A, Dubelko P, Arlehamn C, Crinklaw A, Pomaznoy M . HLA-DR Marks Recently Divided Antigen-Specific Effector CD4 T Cells in Active Tuberculosis Patients. J Immunol. 2021; 207(2):523-533. PMC: 8516689. DOI: 10.4049/jimmunol.2100011. View

18.

Saraiva D, Jacinto A, Borralho P, Braga S, Cabral M . HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy. Front Immunol. 2018; 9:2605. PMC: 6282034. DOI: 10.3389/fimmu.2018.02605. View

19.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

20.

Zhang C, Shi L, Wang F . Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5):428-430. PMC: 7129165. DOI: 10.1016/S2468-1253(20)30057-1. View